Related Experiment Video
Updated: May 25, 2026
12:16
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
Analysis of murine CAR-T cell-mediated cytotoxicity in solid tumor models
Celia Martín-Otal1, Álvaro Gómez-Morón2, Noa Beatriz Martín-Cofreces3
1Queen Mary University of London, Barts Cancer Institute, John Vane Science Centre, London, United Kingdom.
Methods in Cell Biology
|May 23, 2026
Summary
Chimeric Antigen Receptor T-cell (CAR-T) therapy shows promise for blood cancers but faces relapse and solid tumor challenges. This study details methods for generating and assessing mouse CAR-T cell killing ability to improve treatments.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Biology
Background:
- Chimeric Antigen Receptor T-cell (CAR-T) therapy is effective against hematological malignancies like ALL and MM.
- Relapse rates and limited efficacy in solid tumors necessitate improved CAR-T cell strategies.
- Enhancing CAR-T cell antitumor activity is crucial for durable responses.
Purpose of the Study:
- To describe a protocol for generating murine CAR-T cells.
- To detail methods for assessing CAR-T cell lytic capacity.
- To contribute to the development of more effective CAR-T immunotherapies.
Main Methods:
- Generation of murine CAR-T cells.
- Real-time impedance-based assay for cytotoxicity assessment.
- Conventional endpoint cytotoxicity assay for lytic capacity evaluation.
Main Results:
- Established a protocol for murine CAR-T cell generation.
- Validated methods for assessing CAR-T cell lytic function.
- Provided a framework for rigorous CAR-T cell characterization.
Conclusions:
- Standardized protocols are essential for characterizing novel CAR-T cell designs.
- Improved methods for assessing CAR-T cell efficacy are needed.
- This work supports the advancement of CAR-T therapies for challenging cancers.
